Services on Demand
Print version ISSN 0365-0596
On-line version ISSN 1806-4841
An. Bras. Dermatol. vol.77 no.5 Rio de Janeiro Sept./Oct. 2002
CONTINUING MEDICAL EDUCATION
Molecular Genetics of Epidermolysis Bullosa*
Hiram Larangeira de Almeida Jr.
Adjunct Professor of Dermatology, Federal University of Pelotas
New data regarding the molecular aspects of the heterogeneous group of epidermolysis bullosa has brought some important information about its pathogenesis. In epidermolysis bullosa simplex the majority of mutations are localized in the genes of the basal cytokeratin 5 (gene KRT5) and 14 (gene KRT14), cytolysis at this layer with intraepidermal blister is seen under light microscopy. Mutations of plectin (gene PLEC1), a protein found in the inner hemidesmosomal plaque, leads also to intraepidermal blisters. In junctional epidermolysis bullosa many proteins from the basal membrane zone are involved, such as laminin 5 (genes LAMA3, LAMB3 and LAMC2), integrin a6b4 (genes ITGA6 and ITGB4) and collagen XVII (gene COL17A1), the dysfunction which leads to a subepidermal blister, at the level of the lamina lucida. In the third group, epidermolysis bullosa dystrophica, the mutations are localized in only one gene (gene COL7A1), where they alter the structure of collagen VII, the principal compound of anchoring fibrils, splitting the skin under the lamina densa. This information can also be used in the prenatal diagnosis of epidermolysis bullosa, with future perspectives of gene therapy.
Key-words: prenatal diagnosis; epidermolysis bullosa; genetics, biochemical; mutation; polymerase chain reaction.
Before the discovery and standardization of polymerase chain reaction (PCR), gene sequencing was an arduous task, requiring a long time to analyze small segments. PCR allows the fast amplification of DNA segments, which are then sequenced, thereby contributing to enormous progress in this field. To date, inputting PCR as a key word in the Medline database, lists over 150,000 publications using this technique, in a period of little over 12 years, thus illustrating the importance of PCR to medical research.
The principle of PCR is quite simple: the first step is to isolate the DNA, for instance taking blood and making use of its insolubility and precipitation in certain solvents and its water solubility, several commercial kits are available for this function.
Then, part of the DNA obtained is incubated with a thermoresistant polymerase (since the DNA is heated in order to separate the double chain) together with known sequences of DNA, the so-called primers If the DNA in question has the same sequence as that of the primer, the polymerase will amplify this segment of DNA. The nucleotides (adenine, thymidine, cytosine and guanine) are part of the reaction, such that obviously the enzyme has the necessary raw material for the polymerization. Heating and cooling cycles are repeated innumerous times, thereby increasing the product of PCR more and more. After which, electrophoresis is performed to identify the presence of a band of DNA, demonstrating the positivity or otherwise of the reaction.
In a subsequent stage the product obtained by PCR is sequenced using a variant of PCR. The sequencing is now automated with laser readings providing polychromatic graphs, with blue representing cytosine, red thymidine, black guanine and green adenine (Figure 1). Comparison of the result obtained in the investigated patient and their progenitors with the normal gene sequence can demonstrate mutation and an inherited pattern.
Each set of three bases of DNA codifies an amino acid for the protein synthesis in the ribosome; leading to a mutation, or in other words, the change of a base, during the protein synthesis there will be an insertion of another amino acid, thus altering the structure of the protein and resultant consequences.
Countless genes have already been sequenced and their composition is available in digital databases. These can be accessed at the Genbank of the National Center of Biotechnology Information of the United States: www.ncbi.nlm.nih.gov.
The mutations are described by citing the amino acids or bases involved. Firstly the aminoacid/base is given that should constitute the protein/gene, followed by a number, wich corresponds to the location of the same in the protein/gene under investigation and finally the aminoacid/base inserted in the place of the first, such as, for instance, Glu20Arg, in other words, the twentieth amino acid should be a glutamine, but mutation leads to an insertion in the protein of an arginine, wich alters its structure. Some sequences of bases codify the end of the protein synthesis; a mutation can lead to this interruption, the so-called premature termination codon, wich is described in the following manner: Lys472Stop, in other words, instead of the insertion of a lysine, at the 472 position, the protein synthesis was interrupted. Abbreviated descriptions with only a single letter can be found, for example such an interruption of this synthesis is denoted by an X; in the above example this woul then be L472X.
The bullous dermatoses make a fascinating chapter in dermatology, they comprise acquired or congenital defects of the intraepidermal or dermoepidermal adhesion, leading to blisters which can be spontaneous or provoked by minimal trauma.
In epidermolysis bullosa (EB) these defects are congenital and can be identified by gene sequencing, which affords a greater understanding of their molecular base,1,2complements the clinicohistological diagnosis and maybe in the medium term will partly modify the classification of these dermatoses
Three subgroups of EB are recognized:2 epidermolysis bullosa simplex (EBS), in the which the cleaving occurs inside the epidermis; junctional epidermolysis bullosa (EBJ), with subepidermal cleaving in the lamina lucida; and epidermolysis bullosa dystrophica (EBD), also subepidermal, but below the lamina densa. EBJ and EBD cannot be differentiated by optical microscopy alone. There are several classifications, but in this work the second international consensus has been adopted regarding the diagnosis and classification of epidermolysis bullosa.3
Epidermolysis bullosa simplex
The group of EBS has several subtypes, according to the intensity and location of the blisters, all of which with autosomal dominant inheritance;4 these are also called epidermolytic EB, since the defect is intraepidermal.3The histological aspect most commonly found is degeneration of the basal layer, in the absence of any inflammatory infiltration and without deposit of antibodies in the tissue.
The most serious form of EBS is Dowling-Meara syndrome (EBS-DM),5 in which disseminated blisters that also involve the mucous membranes, are accompanied by palmoplantar hyperkeratosis. The mildest form is Weber-Cockayne syndrome (EBS-WC) with lesions restricted to the palmar and plantar regions.5 An intermediate form exists, again with disseminated blisters, but with a less intense picture than that of EBS-DM, denominated EBS-Koebner (EBS-K), although certain authors consider this to be a mild variant of EBS-DM.6
Some cytokeratins are expressed in the epithelial cells in pairs,7 which form heterodimers, in other words, the union of two molecules, configuring the cytoskeleton of the epithelia, with specificity according to the epithelium involved.7 The basal layer differs from other epithelia and suprabasal segments of the epidermis by the expression of cytokeratins 5 and 14.
Cytokeratins 5 and 14 are regulated by the genes KRT5 and KRT14, located in chromosomes 17 and 12, respectively. It is interesting to note that different genetic defects in EBS, one affecting cytokeratin 5 and the other14,6,8,9lead to the same histological alteration, because all these defects produce structural alterations in one or another cytokeratin,10 impeding their structural function in the cytoskeleton11 - i.e. the formation of the heterodimers, responsible for the three-dimensional configuration of the cell. This alteration is easily seen in the histology and culminates with the formation of blisters, making this the only subgroup of EB due to cytolysis and not to an adhesion defect.
The cytokeratins are constituted by four helical segments, 1A, 1B, 2A and 2B,12the majority of the mutations of EBS-DM are described in the beginning of segment 1A and at the end of segment 2B (Figure 2)13,14 of the basal cytokeratins. The mutations of EBS-K have a similar location,15 reinforcing the hypothesis that it is a variant of EBS-DM. In EBS-WC most of the mutations are located in the non-helical segment between 1B and 2A of the same cytokeratins, though this does not explain the palmoplantar location of the lesions.
A fourth type of EBS is described, in which cytolysis in the basal layer does not occur. It is EBS with tardive muscular dystrophy, due to alteration of the plectin, present in the internal plaque of the hemidesmosome (Figure 3). Since the cleaving occurs within the epidermis, it is included in this group. The plectin is regulated by the gene PLEC11 and is also involved in the cytoskeleton of the smooth musculature,16 hence the associated myopathy.1,17 Another component of the internal plaque of the hemidesmosome is the bullous pemphigoid antigen with 230 KD molecular weight. To date mutation in the gene that regulates this has not been described.1
Junctional Epidermolysis Bullosa
Given the complexity of the basal membrane zone, alterations in several proteins involved in the dermoepidermal adhesion can lead to the various clinical pictures of EBJ; for these molecular alterations to be understood, it is important to be familiar with the substances responsible for the adhesion between the basal keratinocytes and the collagen IV - the lamina densa (Figure 3).
The antigen of bullous pemphigoid (180 KD) and integrin a6b4, which are transmembranous proteins, are found in the external plaque.18
The antigen of bullous pemphigoid (180 KD) is in reality a transmembranous collagen, denominated collagen XVII, and is regulated by the gene COL17A1.1Each segment of the integrin a6b4 is regulated by two different genes, ITGA6 and ITGB4, which are also expressed in the skin and digestive tract.1,18
Finally, some substances present in the lamina lucida complement this molecular net,1 of which the most important is laminin 5. The laminins are heterotrimers, or that is, they are constituted by three distinct classes of polypeptides a, b and g,18-20 and hence regulated by three genes. Laminin 5 is composed of one a3, one b3 and one g2, regulated by the genes LAMA3, LAMB3 and LAMC2, respectively.
An absence or alteration of these substances produces a rupture of this adhesion net, with the formation of blisters.2 Some mutations occur due to the so-called premature termination codon (PTC), which provokes an interruption of the protein synthesis and consequently absence of protein in the tissue, resulting in a more serious clinical picture.
Several genophenotype correlations have already been made. Such as integrin a6b4 is expressed in the skin and intestine, mutations of which lead to forms of EBJ with atresia pilori, the clinical picture varies according to whether or not it is associated to PTC.
Regarding generalized, benign and atrophic EBJ, characterized by disseminated blisters with nail dystrophy, in which the immunohistochemistry with antibody against collagen XVII is negative, PTC has been demonstrated in the gene COL17A,1,21 which correlates with the tissular absence of collagen XVII. Some authors denominate this form non-Herlitz EBJ, as it presents a mild course and normal life expectancy.21,22
Similar to the mutations in components of the hemidesmosome described above, mutations in the laminin also provoke dislocation of the epidermis. Most of the mutations of the genes of laminin 5 lead to PTC, provoking absence of the protein and intense clinical picture,23,24 characterized by disseminated lesions also affecting the mucous membranes,23 with low survival in function of bacterial complications, denominated Herlitz syndrome or epidermolysis bullosa lethalis.
The alterations have already been demonstrated in the three genes that codify laminin 5,25 without a phenotype difference according to the segment involved,26 suggesting that all are important for its adhesion function.26,27 Eighty percent of the mutations reside in the gene LAMB3,22,24,28-30 30 two of these are recurrent (R635X and R42X),26,28 which amount to half of the mutations in LAMB3.1 In this gene alone 35 different mutations have already been reported.22
There are reports of mutation in laminin 5 among patients in which the immunohistochemistry demonstrated a reduction in laminin 5, but not a complete absence, as in Herlitz Syndrome, and consequently the clinical picture was not so serious.31,32 These forms have also been denominated non-Herlitz EBJ,33 which are clinically similar to the forms arising from mutation of collagen XVII.33
All forms of EBJ are inherited as an autosomal recessive trait.23
Epidermolysis bullosa dystrophica
The main clinical characteristic of EBD is scarring after tissue loss, since the separation occurs below the lamina densa.34 As in the other groups, there are variants reflecting the clinical picture; in spite of these variants, the genetic defect is located in a single gene, COL7A1.35 This gene is responsible for codifying collagen VII, the main representative of the anchoring fibrils,35 which participate in the adherence of the lamina densa to the dermis (Figure 3), hence it is also denominated dermolytic EB. In this group there are forms inherited as autosomal dominant and recessive traits.
In order to understand the correlation between genotype and phenotype in EBD it is necessary to also understand the role of collagen VII in the dermoepidermal adhesion.
This is produced by the keratinocytes and has a triple helix configuration of collagen, preceded and followed by non-collagen segments (NC-1 and NC-2, respectively).36,37 In the center of the triple helix there is small non-collagen segment, which probably provides flexibility to the protein. Later, at the extracellular level, a fusion occurs between two of these molecules with loss of the NC-2 segment, forming antiparallel dimers. The union of several dimers forms the anchoring fibrils34,36,37 (Figure 4).
Three subtypes of EBD are well characterized: recessive EBD Halloupeau-Siemens (EBD-RHS), with an intense clinical picture, producing acral retractions with synechiae of the digits and involvement of the digestive tract;37recessive EBD mitis (EBD-RM), in which the clinical picture is much less intense in comparison with that of EBD-RHS, with localized lesions in the areas of greatest trauma, such as the knees and extremities; and the dominant form (EBD-D), with a similar picture to that of EBD-RM,37 associated to nail dystrophy and, in some cases, with white papular lesions.
Electron microscopy and immunohistochemical characterization with antibodies against collagen VII show alteration in the anchoring fibrils to the extent of their absence in EBD-RHS and reduction in the milder forms, EBD-RM and EBD-D.38 In some cases the immunohistochemistry is positive but without anchoring fibrils revealed by electron microscopy, which demonstrates the presence of part of the molecule, but with structural alteration.38
The identification of the mutations responsible for EBD has brought a greater understanding of this spectrum (Figure 5).
In EBD-RHS the genetic alteration is a PTC, with consequent interruption in the synthesis of collagen VII,39 which correlates with the intensity of the clinical picture and with the findings of electron microscopy and immunohistochemistry, in which the anchoring fibrils are not detected.34,37
In EBD-RM the greater part of the mutations occur at the end of the collagen segment and in NC-2, interfering in the formation of the antiparallel dimers and altering the compliance of the protein, though these continue present, giving rise to a milder clinical picture and the presence of anchoring fibrils in the electron microscopy.37,40
In EBD-D, the characteristic alteration is the substitution of a glycine in the collagen segment,41,42 altering its stability and maybe propitiating its degradation.36,37,43 As in EBD-RM, the anchorage fibrils are present, but their function is impaired. Most of the mutations are located immediately after the non-collagen segment of the center of the triple helix;42 the G2043R mutation is the most commonly described.36,41 Likewise it has already been demonstrated that the functional alteration of the anchoring fibrils depends on the location in which the glycine is substituted,34,44 which in turn contributes to the clinical variability. As yet, there is no convincing explanation as to why the glycine substitution is an inherited dominant trait.
The majority of cases involving the pretibial form of EBD are autosomal dominant and the substitution of glycine has also been described.45 Recessive cases have been published,45 these could equally be considered variants of the mild forms of EBD, the reason behind the localized occurrence of the lesions is not known.
About 100 different mutations have already been described in EBD,34 and are found in 80% of the cases examined.37 As in other forms of EB, some mutations are not defined within the above described outline, because, for instance, some substitutions of glycine have been found in EBD-RM;37,40,41 to date, it has yet to be clarified why in these cases the progenitors that present such glycine substitution may be normal, or in other words, the mutation is not dominant and is only expressed in a recessive manner, with the inheritance of two changed alleles.41
Various intermediate clinical pictures, presenting difficult clinical classification, have already been described with such uncommon mutations, for instance, recessive EBD with PTC in one allele and a glycine substitution in the other.46
The new molecular aspects, involving both genes and proteins, demonstrate just how varied the spectrum of EB can be (Table 1). In EBS the genetic defects of the basal cytokeratins produce a histological alteration due to the modification of the cytoskeleton in the basal layer of the epidermis, in that alteration of the plectin, a component of the internal plaque of the hemidesmosome, also leads to the intraepidermal separation. In EBJ several genes are involved, due to the complexity of the basal membrane zone, but all lead to the dislocation of the basal keratinocytes of the lamina densa, in other words, the cleaving occurs in the lamina lucida. Finally, in EBD only one gene is modified, altering the collagen VII, cleaving below the lamina densa, but even so with phenotype variation, according to the consequence of the mutation.
Despite its important contribution to progress in the understanding of these illnesses, gene sequencing should be used together with clinical, histological, electron microscopy and immunohistochemical findings in the diagnosis of EB.47
Another important application for molecular genetics is in prenatal diagnosis (PND),2,48 examining fetal DNA obtained from the chorion rather than the fetal skin. PND performed on the basis of the lesions requires the collection of a skin specimen, which should be representative of the illness, in order to avoid a false-negative result, one should wait until the eighteenth or twentieth week.43Sequencing has the advantage that it can be performed around the tenth week, which means that a more precocious decision to terminate the gestation can be made in those countries in which this procedure is permitted. Furthermore, complications arising from fetoscopy with biopsy occur in between four to 7% of cases compared to 1% in chorionic biopsy.43
Genetic sequencing has already been used in PND for all forms of EB,23,24,43,49-51 and has already been performed before implantation, based on a cell obtained from an embryo with a number of cells varying from five to eight.52
Genetic counseling is another important application of this new information, since it helps to explain the inheritance pattern, especially when dealing with frequent and well-known mutations. Also in the case of de novo mutations, when the DNA exam of the progenitors is normal and the mutation is only found in the patient, it can be affirmed that the risk factor for the next gestation is very low. Regarding the patient's offspring, this will depend on whether the type of mutation found, is dominant or recessive,42 present in only one allele or both.
In function of this recent information regarding gene expression,53 there are new therapeutic perspectives for EB, although these are still in an experimental phase. There have already been reports of ex vivo manipulation of keratinocytes from patients with EBJ, unable to produce theb3 chain of laminin 5, which, after gene transfer, were demonstrated to be capable - albeit transitorily - of synthesizing it, thereby opening new therapeutic perspectives for this group of genodermatoses.54 Animal models using transgenic mice to simulate human disease, has been contributing information relevant to the research of EB.10,12
Some authors consider that research into the correlation between genotype and phenotype is just at the beginning34 and that the expansion of the databases on gene alterations is of extreme importance, since it will enable an ever increasingly improved correlation and perhaps even a reclassification of some genodermatoses based on molecular aspects.38
1. Pulkkinen L, Uitto J. Mutation analysis and molecular genetics of epidermolysis bullosa. Matrix Biol 1999;18:29-42. [ Links ]
2. Uitto J, Pulkkinen L. Molecular genetics of heritable blistering disorders. Arch Dermatol 2001; 137: 1458-61. [ Links ]
3. Fine JD, Eady RAJ, Bauer EA, et al. Revised classification system for inherited epidermolysis bullosa: report of the second international consensus meeting on diagnosis ans classification of epidermolysis bullosa. J Am Acad 2000;42:1051-66. [ Links ]
4. Müller FB, Küster W, Tuderman LB, Korge BP. Novel K5 and K14 mutations in German patients with the Weber-Cockayne variant of epidermolysis bullosa simplex. J Invest Dermatol 1998; 111:900-2. [ Links ]
5. Horn HM, Tidman MJ. The clinical spectrum of epidermolysis bullosa simplex. Br J Dermatol 2000; 142: 468-72. [ Links ]
6. Shemanko CS, Mellerio JE, Tidman MJ, Lane EB, Eady RAJ. Severe palmo-plantar hyperkeratosis in Dowling-Meara epidermolysis bullosa simplex caused by a mutation in the keratin 14 gene (KRT14). J Invest Dermatol 1998; 111:893-5. [ Links ]
7. Irvine AD, Mclean WHI. Human keratin diseases: the increasing spectrum of disease and sublety of the phenotype-genotype correlation. Br J Dermatol 1999; 140: 815-28. [ Links ]
8. Sasaki Y, Shimizu H, Akiyama M, et al. A recurrent keratin 14 mutation in Dowling-Meara epidermolysis bullosa simplex . Br J Dermatol 1999; 141: 747-8. [ Links ]
9. Livingston RJ, Sybert VP, Smith LT, Dale BA, Presland RB, Stephens K. Expression of a truncated keratin 5 may contribute to severe palmo-plantar hyperkeratosis in epidermolysis bullosa simplex patients. J Invest Dermatol 2001; 116:970-4. [ Links ]
10. Peters B, Kirfel J, Büssow H, Vidal M, Magin TM. Complete cytolysis and neonatal lethality in keratin 5 knockout mice reveal its fundamental role in skin integrity and in epidermolysis bullosa simplex. Mol Biol Cell 2001; 12: 1775-89. [ Links ]
11. Ma L, Yamada S, Wirtz D, Coulombe PA. A hot-spot mutation alters the mechanical properties of keratin filament networks. Nat Cell Biol 2001; 3: 503-6. [ Links ]
12. Cao T, Longley MA, Wang XJ, Roop DR. An inducible mouse model for epidermolysis bullosa simplex: implications for gene therapy. J Cell Biol 2001; 152: 651-6. [ Links ]
13. Batta K, Rugg EL, Wilson NJ, et al. A keratin 14 knockout mutation in recessive epidermolysis bullosa simplex resulting in less severe disease. Br J Dermatol 2000; 143: 621-7. [ Links ]
14. Müller FB, Almeida Jr. HL, Schumann H, et al. An update on keratin mutations in epidermolysis bullosa simplex Dowling-Meara (in press). [ Links ]
15. Liovic M, Stojan J, Bowden PE, et al. A novel keratin 5 mutation (K5V186L) in a family with EBS-K: a conservative substitution can lead to development of different disease phenotypes. J Invest Dermatol 2001; 116: 964-9. [ Links ]
16. Bauer JW, Rouan F, Kofler B, et al. A compound heterozygous one amino-acid insertion/nonsense mutation in the plectin gene causes epidermolysis bullosa simplex with plectin deficiency. Am J Pathol 2001; 158: 617-25. [ Links ]
17. Kurose K, Mori O, Hashisuka H, Shimizu H, Owaribe K, Hashimoto T. Cultured keratinocytes from plectin/HD1-deficient epidermolysis bullosa simplex showed altered ability of adhesion to the matrix. J Dermatol Sci 2000; 24: 184-9. [ Links ]
18. Nievers MG, Schaapveld RQJ, Sonnenberg A. Biology and function of hemidesmossomes. Matrix Biol 1999; 18:5-17. [ Links ]
19. Aumailley M, Krieg T. Laminins: a family of diverse multifunctional molecules of basement membranes. J Invest Dermatol 1996;106:209-14. [ Links ]
20. Aumailley M, Rousselle P. Laminins of the dermo-epidermal junction. Matrix Biol 1999; 18:19-28. [ Links ]
21. Ruzzi L, Pas H, Posteraro P, et al. A homozygous nonsense mutation in type XVII collagen gene (COL17A1) uncovers an alternatively spliced mRNA accounting for an unusually mild form of non-Herlitz junctional epidermolysis bullosa. J Invest Dermatol 2001; 116:182-7. [ Links ]
22. Nakano A, Pfendner E, Pulkkinen L, Hashimoto I, Uitto J. Herlitz junctional epidermolysis bullosa: novel and recurrent mutations in the LAMB3 gene and the population carrier frequency. J Invest Dermatol 2000; 115:493-8. [ Links ]
23. Vailly J, Pulkkinen L, Miguel C, et al. Identification of a homozygous one-basepair deletion in exon 14 of the LAMB3 gene in a patient with Herlitz junctional epidermolysis. bullosa and prenatal diagnosis in a family at risk for recurrence. J Invest Dermatol 1995; 104:462-6. [ Links ]
24. Takizawa Y, Shimizu H, Pulkkinen L, et al. Novel mutations in the LAMB3 gene shared by two japanese unrelated families with Herlitz junctional epidermolysis bullosa, and their application for prenatal testing. J Invest Dermatol 1998; 110:174-8. [ Links ]
25. Takizawa Y, Shimizu H, Pulkkinen L, et al. Novel premature termination codon mutations in the laminin 2-chain gene (LAMC2) in Herlitz junctional epidermolysis bullosa. J Invest Dermatol 1998; 111:1233-4. [ Links ]
26. Pulkkinen L, Meneguzzi G, Mcgrath JA, et al. Predominance ot the recurrent mutation R635X in the LAMB3 gene in european patients with Herlitz junctional epidermolysis bullosa has implications for mutation detection strategy. J Invest Dermatol 1997; 109:232-7. [ Links ]
27. Mcgrath JA, Kivirikko S, Ciatti S, Moss C, Christiano AM, Uitto J. A recurrent homozygous nonsense mutation within the LAMA3 gene as a cause of Herlitz junctional epidermolysis bullosa in patients of pakistani ancestry: evidence for a founder effect. J Invest Dermatol 1996; 106:781-4. [ Links ]
28. Cserhalmi PB, Horvath A, Boros V, et al. Identification ot the LAMB3 hotspot mutation R635X in a hungarian case of Herlitz junctional epidermolysis bullosa. Exp Dermatol 1997;6:70-4. [ Links ]
29. Takizawa Y, Shimizu H, Pulkkinen L, et al. Combination of a novel frameshift mutation (1929delCA) and a recurrent nonsense mutation (W610X) of the LAMB3 gene in a japanese patient with Herlitz junctional epidermolysis bullosa, and their application for prenatal testing. J Invest Dermatol 1998; 111:1239-40. [ Links ]
30. Hauschild R, Wollina U, Tuderman LB. Junctional epidermolysis bullosa gravis (Herlitz): diagnostic and genetic aspects. J Eu Acad Dermatol Venereol 2001; 15: 73-6. [ Links ]
31. Christiano AM, Pulkkinen L, Eady RAJ, Uitto J. Compound heterozygosity for nonsense and missense mutations in the LAMB3 gene in nonlethal junctional epidermolysis bullosa. J Invest Dermatol 1996; 106:775-7. [ Links ]
32. Mcgrath JA, Pulkkinen L, Christiano AM, Leigh IM, Eady RAJ, Uitto J. Altered laminin 5 expression due to mutations in the gene encoding the ß3 chain (LAMB3) in generalized atrophic benign epidermolysis bullosa. J Invest Dermatol 1995; 104:467-74. [ Links ]
33. Inoue M, Tamai K, Shimizu H. A homozygous missense mutation in the cytoplasmatic tail of ß4 integrin, G931D, that disrupts hemidesmossome assembly and underlies non- Herlitz junctional epidermolysis bullosa without pyoric atresia? J Invest Dermatol 2000; 114:1061-3. [ Links ]
34. Tuderman LB, Höpfner B, Hauasli NH. Biology of anchoring fibrils: lessons from dystrophic epidermolysis bullosa. Matrix Biol 1999; 18: 43-54. [ Links ]
35. Christiano AM, Hoffman GG, Honet LCC, et al . Structural organization of the human type VII collagen gene (COL7A1), composed of more exons than any previously characterized gene. Genomics 1994; 21: 169-79. [ Links ]
36. Mellerio JE, Alanis JCS, Talamantes ML, et al. A recurrent glycine substitution mutation, G2043R, in the type VII collagen gene (COL7A1) in dominant dystrophic epidermolysis bullosa. Br J Dermatol 1998; 139: 730-7. [ Links ]
37. Järvikallio A, Pulkkinen L, Uitto J. Molecular basis of dystrophic epidermolysis bullosa: mutations in the type VII collagen gene (COL7A1). Human Mut 1997; 10: 338-47. [ Links ]
38. Kon A, Pulkkinen L, Yamamoto AI, Hashimoto I, Uitto J. Novel COL7A1 mutations in dystrophic forms of epidermolysis bullosa. J Invest Dermatol 1998; 111:534-7. [ Links ]
39. Christiano AM, Anhalt G, Gibbons S, Bauer EA, Uitto J. Premature termination codons in the type VII collagen gene (COL7A1) underlie severe, mutilating recessive dystrophic epidermolysis bullosa. Genomics 1994; 21: 160-8. [ Links ]
40. Ryoo YW, Kim BC, Lee KS. Characterization of mutations of the type VII collagen gene (COL7A1) in recessive dystrophic epidermolysis bullosa mitis (M-RDEB) from three Korean patients. J Dermatol Sci 2001; 26: 125-32. [ Links ]
41. Rouan F, Pulkkinen L, Jonkman MF, et al. Novel and de novo glycine substitution mutations in the type VII collagen gene (COL7A1) in dystrophic epidermolysis bullosa: implications for genetic counseling. J Invest Dermatol 1998; 111:1210-13. [ Links ]
42. Lee YY, Li C, Chao SC, Pulkkinen L, Uitto J. A de novo glycine substitution mutation in the collagenous domain of COL7A1 in dominant dystrophic epidermolysis bullosa. Arch Dermatol Res 2000; 292: 159-63. [ Links ]
43. Klingberg S, Mortimore R, Parkes J, et al. Prenatal diagnosis of dominant dystrophic epidermolysis bullosa, by COL7A1 molecular analysis. Prenat Diagn 2000; 20: 618-22. [ Links ]
44. Murata T, Masunaga T, Shimizu H, et al. Glycine substitution mutations by different amino acids in the same codon of COL7A1 lead to heteregeneous clinical phenotypes of dominant dystrophic epidermolysis bullosa. Arch Dermatol Res 2000; 292: 477-81. [ Links ]
45. Betts CM, Posteraro P, Costa AM, et al. Pretibial dystrophic epidermolysis bullosa: a recessively inherited COL7A1 splice site mutation affecting procollagen VII processing. Br J Dermatol 1999; 141: 833-39. [ Links ]
46. Nordal EJ, Mecklenbeck S, Hausser I, Skranes J, Tuderman LB, Dahl TG . Generalized dystrophic epidermolysis bullosa: identification of a novel, homozygous glycine substitution, G2031S, in exon 73 of COL7A1 in monozygous triplets.Br J Dermatol 2001; 144: 151-7. [ Links ]
47. Mcgrath JA, Ashton GHS, Mellerio JE, et al. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations. J Invest Dermatol 1999; 113:314-21. [ Links ]
48. Klausegger A, Pulkkinen L, Gubo GP, et al. Is screening of the candidate gene necessary in unrelated partners of members of families with Herlitz junctional epidermolysis bullosa? J Invest Dermatol 2001; 116:474-5. [ Links ]
49. Christiano AM, Pulkkinen L, Mcgrath JA, Uitto J. Mutation-based prenatal diagnosis of Herlitz junctional epidermolysis bullosa. Prenat Diagn 1997; 17: 343-54. [ Links ]
50. Hovnonian A, Hilal L, Bardon CB, et al. DNA-based prenatal diagnosis of generalized recessive dystrophic epidermolysis bullosa in six pregnancies at risk for recurrence. J Invest Dermatol 1995; 104:456-61. [ Links ]
51. Rugg EL, Baty D, Shemanko CS, et al. DNA based prenatal testing for the skin blistering disorder epidermolysis bullosa simplex. Prenat Diagn 2000;20:371-7. [ Links ]
52. Friedman PBC, Tang Y, Adler A, Krey L, Grifo JA, Christiano AM. Preimplantation genetic diagnosis in two families at risk for recurrence of Herlitz junctional epidermolysis bullosa. Exp Dermatol 2000; 9:290-7. [ Links ]
53. Khavari PA. Gene therapy for genetic skin disease. J Invest Dermatol 1998; 110:462-6. [ Links ]
54. Vailly J, Palacios LG, Dell'Ambra E, et al. Corrective gene transfer of keratinocytes from patients with junctional epidermolysis bullosa restores assembly of hemidesmossomes in reconstructed epithelia. Gene Ther 1998; 5: 1322-32. [ Links ]
Prof. Dr. Hiram Larangeira de Almeida Jr.
Departamento de Medicina Especializada
Faculdade de Medicina da UFPEL
Av. Duque de Caxias, 250
Pelotas RS 96030-002
Received in January,
30th of 2002.
Approved by the Consultive Council and accepted for publication in July, 30th of 2002.
*Work done with a post-doctorate grant from Capes and the Alexander von Humbold Foundation, in the Genetic Diagnosis Laboratory, University of Cologne, Germany (Service of Prof. Thomas Krieg)